Fueling fibrosis in chronic hepatitis C

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 36, 2012, Pages 14293-14294

  Bataller, Ramon ^a   Lemon, Stanley M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; HEPATITIS C; HUMAN; IMMUNE SYSTEM; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EVOLUTION, MOLECULAR; HEPACIVIRUS; HEPATITIS C; LIVER CIRRHOSIS;

HEPATITIS C VIRUS;

EID: 84865997790     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1212048109     Document Type: Note

References (17)

1. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(suppl 1):i36-i46.
2. Kwong JC, et al. (2012) The impact of infection on population health: Results of the Ontario Burden of Infectious Disease Study. PLoS ONE, in press.
3. Ly KN, et al. (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156:271-278.
4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:513-521.
5. Farci P, et al. (2012) Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci USA 109:14562-14567.
6. Altevogt BM, Pankevich DE, Shelton-Davenport MK, Kahn JP, eds (2011) Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity (National Academy Press, Washington, DC).
7. Kato N, et al. (1993) Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67:3923-3930. (Pubitemid 23180716)
8. Walker CM (2010) Adaptive immunity to the hepatitis C virus. Adv Virus Res 78:43-86.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
10. Marcolongo M, et al. (2009) A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 50:1038-1044.
11. Liang Y, et al. (2009) Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137:1448-1458.
12. Korenaga M, et al. (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280:37481-37488. (Pubitemid 41642356)
13. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126:529-540. (Pubitemid 38182310)
14. Marra F, et al. (1999) Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 29:140-148. (Pubitemid 29023996)
15. Mühlbauer M, et al. (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125:1085-1093.
16. Colmenero J, et al. (2009) Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 297:G726-G734.
17. Micheloud D, et al. (2009) Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 11:183-188.